Ceribell raises 2026 revenue guidance to $114–117M following strong Q2 with 33% YoY growth

Ceribell/Clarity Rapid-Response EEG

Ceribell reported Q2 2026 revenue of $28.1 million, up 33% year-over-year, and raised its full-year 2026 revenue guidance to $114–117 million, representing 28–31% growth. The increase reflects strong utilization at existing hospital accounts and continued customer additions.

• Q2 2026 revenue reached $28.1M, driven by increased ICU EEG adoption and higher utilization rates.
• Guidance excludes material contributions from newly cleared neonatal, pediatric and delirium products, expected to accelerate revenue in 2027.
• The company cited strong momentum in core seizure detection business with continued hospital customer expansion.